Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for calf muscle spasticity in hereditary spastic paraplegia
2009-012073-34Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in hereditary spastic paraplegia (HSP), sponsored by Radboud University Medical Center. Primary endpoint: Dynamic balance success rate after external perturbations. Started May 2009; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
hereditary spastic paraplegia (HSP)
Beyond the preview
Go deeper on 2009-012073-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012073-34.